Quality of life: a crucial aspect for the patients, a neglected goal in the treatment of anemia in patients with CKD
- 18 May 2023
- journal article
- editorial
- Published by Elsevier in Kidney International
- Vol. 103 (6) , 1025-1027
Abstract
No abstract availableKeywords
Funding Information
- Astellas Pharma US
- Vifor Pharma
This publication has 9 references indexed in Scilit:
- The ASCEND-NHQ randomized trial found positive effects of daprodustat on hemoglobin and quality of life in patients with non-dialysis chronic kidney diseaseKidney International, 2023
- Validity and reliability of the Patient-Reported Outcomes Measurement Information System (PROMIS®) using computerized adaptive testing in patients with advanced chronic kidney diseaseNephrology Dialysis Transplantation, 2022
- Renal association clinical practice guideline on Anaemia of Chronic Kidney DiseaseBMC Nephrology, 2017
- Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statementNephrology Dialysis Transplantation, 2013
- Darbepoetin Alfa Impact on Health Status in Diabetes Patients with Kidney DiseaseClinical Journal of the American Society of Nephrology, 2011
- A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney DiseaseNew England Journal of Medicine, 2009
- Interpreting score differences in the SF-36 Vitality scale: using clinical conditions and functional outcomes to define the minimally important differenceCurrent Medical Research and Opinion, 2007
- Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and AnemiaNew England Journal of Medicine, 2006
- The Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Who Are Receiving Hemodialysis and EpoetinNew England Journal of Medicine, 1998